FDA Panel Discusses Antidepressants During Pregnancy amid Controversy

Health and Human Services Secretary Robert F. Kennedy Jr. has long criticized antidepressants, claiming—without solid evidence—that they may cause addiction and contribute to school shootings. He has even proposed sending individuals on these medications to “wellness farms,” where they can grow organic food, receive re-parenting, and gradually discontinue their medications.

Recently, the FDA convened an expert panel to review the use of selective serotonin reuptake inhibitors (SSRIs)—a common class of antidepressants—during pregnancy. The two-hour livestreamed session included researchers, psychologists, and practitioners discussing the potential impacts on maternal and fetal health. While about 13% of Americans use antidepressants, only a smaller percentage of pregnant women—around 6-10%—are on them, with some studies indicating risks for preterm birth and developmental issues.

Many panelists, including several critics of antidepressant use, reiterated misleading claims about the biological basis of depression and anxiety, often dismissing the reality of perinatal mental health conditions. This prompted a strong critique from the president of the American College of Obstetricians and Gynecologists, who described the session as “alarmingly unbalanced” and emphasizing the importance of addressing untreated mood disorders during pregnancy.

Research highlights that postpartum depression affects approximately one in eight women, with untreated cases linked to bonding difficulties, developmental delays, and increased maternal mortality. Recent studies also suggest that the overturning of Roe v. Wade has led to a rise in PPD diagnoses in states with abortion bans, underscoring the urgency of proper mental health care.

Despite scientific consensus, panelists questioned the safety of antidepressants during pregnancy, citing studies that suggested risks of autism and alleged data withholding by doctors. Experts like Wendy Davis and Dr. Kay Roussos-Ross defended medication use, emphasizing that untreated depression poses significant risks, including preterm labor and developmental problems, and that medications can be life-saving for many women.

While some panelists called for stricter warnings about SSRI risks, current evidence indicates these drugs have minimal or negligible effects on fetal health. The consensus among health professionals remains that appropriate treatment, including medication if necessary, is critical for maternal and child well-being.